###begin article-title 0
Colorectal carcinomas in MUTYH-associated polyposis display histopathological similarities to microsatellite unstable carcinomas
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 210 218 <span type="species:ncbi:9606">patients</span>
MUTYH-associated polyposis (MAP) is a recessively inherited disorder which predisposes biallelic carriers for a high risk of polyposis and colorectal carcinoma (CRC). Since about one third of the biallelic MAP patients in population based CRC series has no adenomas, this study aimed to identify specific clinicopathological characteristics of MAP CRCs and compare these with reported data on sporadic and Lynch CRCs.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 235 240 233 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2</italic>
###xml 279 287 277 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC, p53</italic>
###xml 293 299 291 297 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4 </italic>
###xml 12 20 <span type="species:ncbi:9606">patients</span>
From 44 MAP patients who developed >/= 1 CRCs, 42 of 58 tumours were analyzed histologically and 35 immunohistochemically for p53 and beta-catenin. Cell densities of CD3, CD8, CD57, and granzyme B positive lymphocytes were determined. KRAS2, the mutation cluster region (MCR) of APC, p53, and SMAD4 were analyzed for somatic mutations.
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 336 340 336 340 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 399 405 399 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 463 467 463 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 471 476 471 476 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4</italic>
MAP CRCs frequently localized to the proximal colon (69%, 40/58), were mucinous in 21% (9/42), and had a conspicuous Crohn's like infiltrate reaction in 33% (13/40); all of these parameters occurred at a higher rate than reported for sporadic CRCs. Tumour infiltrating lymphocytes (TILs) were also highly prevalent in MAP CRCs. Somatic APC MCR mutations occurred in 14% (5/36) while 64% (23/36) had KRAS2 mutations (22/23 c.34G>T). G>T tranversions were found in p53 and SMAD4, although the relative frequency compared to other mutations was low.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 353 357 353 357 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 361 367 361 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 416 420 416 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P53 </italic>
###xml 424 430 424 430 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4 </italic>
###xml 510 516 510 516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">early </italic>
MAP CRCs show some similarities to micro-satellite unstable cancers, with a preferential proximal location, a high rate of mucinous histotype and increased presence of TILs. These features should direct the practicing pathologist towards a MAP aetiology of CRC as an alternative for a mismatch repair deficient cause. High frequent G>T transversions in APC and KRAS2 (mutated in early tumour development) but not in P53 and SMAD4 (implicated in tumour progression) might indicate a predominant MUTYH effect in early carcinogenesis.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 152 153 152 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 172 178 172 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUTYH </italic>
###xml 264 265 264 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 266 267 266 267 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 353 359 353 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUTYH </italic>
###xml 473 474 473 474 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 475 476 475 476 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 477 478 477 478 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 479 480 479 480 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 551 557 551 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUTYH </italic>
###xml 574 582 <span type="species:ncbi:9606">patients</span>
MUTYH-associated polyposis (MAP) is an autosomal recessive disorder, which may be responsible for approximately 0.5-1% of colorectal carcinomas (CRCs).[1,2] Most biallelic MUTYH mutation carriers are reported to develop multiple polyps (typically between 10-500).[3,4] However, in seven population based CRC studies, 15 out of 39 (38%) proven biallelic MUTYH mutation carriers had no polyps besides their CRC while seven (18%) had a limited number of adenomas (i.e. <10). [1,2,5-9] Therefore, the practicing pathologist should also consider biallelic MUTYH mutations in CRC patients with none or less than 10 polyps.
###end p 11
###begin p 12
###xml 561 565 561 565 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 727 733 727 733 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 861 863 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 954 956 954 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
The MUTYH protein is a base excision repair (BER) glycosylase involved in the repair of DNA damage resulting from the oxidation of guanine nucleotides. The oxidation product of guanine, 8-oxo-7,8-dihydro-2'-deoxyguanosine (8-oxoG), readily mispairs with adenosine nucleotides during DNA replication. MUTYH acts by scanning the newly synthesized DNA strand for any mispaired adenines, either with guanines or 8-oxoG's, and excising them. A dysfunctional MUTYH protein increases the occurrence of somatic G>T transversions. For instance, somatic mutations in the APC gene in MAP tumours involve almost exclusively G>T transversions, an observation that led to the discovery of the MAP syndrome.[10] Similarly, the most prevalent KRAS2 mutation in MAP tumours is a G>T transversion at codon 12 (c.34G>T), which was reported to be present in 64% of MAP carcinomas.[11] Such mutation is infrequent in sporadic CRCs, according to published consecutive series.[12]
###end p 12
###begin p 13
###xml 433 435 433 435 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
Recently it was reported that MAP CRCs are often near-diploid (52%) and commonly contain chromosomal regions of copy neutral loss of heterozygosity (LOH) (71%). In copy-neutral LOH there is no loss of genetic material and this can arise via mitotic recombination, non-disjunction, or deletion and reduplication events. This is in contrast to sporadic colon cancer, where physical loss of genetic material is the main characteristic.[13]
###end p 13
###begin p 14
###xml 274 279 274 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">hMLH1</italic>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 749 756 <span type="species:ncbi:9606">patient</span>
Another set of CRCs with deficiencies in DNA repair are the mismatch repair deficient tumours. Mismatch repair deficient CRCs with high-microsatellite instability (MSI-high) arise in the context of the Lynch syndrome or have a sporadic origin due to somatic inactivation of hMLH1. MSI-high tumours have characteristic histological and molecular features: they are most often near-diploid and arise preferentially in the right side of the colon. They have a high prevalence of mucinous and medullary histotypes, poor differentiation, a Crohn's-like lymphocytic reaction, and a high amount of (intra-epithelial) tumour infiltrating lymphocytes (TILs). These characteristics are currently employed for diagnostic purposes and may have implications for patient treatment and prognosis. [14-17]
###end p 14
###begin p 15
In the present study we describe histological and molecular aspects of MAP carcinomas in a Dutch cohort, and compare these with data available in literature of consecutive series of sporadic, MSI-high (sporadic), and Lynch syndrome-derived CRCs. The aim of this study was to identify specific characteristics that would aid in the diagnosis of MAP CRCs and in differentiation from carcinomas arising from distinct genetic backgrounds.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients
###end title 17
###begin p 18
###xml 306 312 306 312 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUTYH </italic>
###xml 353 359 353 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUTYH </italic>
###xml 440 441 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 623 632 623 632 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in situ) </italic>
###xml 246 254 <span type="species:ncbi:9606">patients</span>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
###xml 447 454 <span type="species:ncbi:9606">patient</span>
###xml 794 802 <span type="species:ncbi:9606">patients</span>
###xml 959 967 <span type="species:ncbi:9606">patients</span>
Fifty-seven MAP families, from which clinical data were available, were studied. Informed consent was obtained according to protocols approved by the Leiden University Medical Center ethics review board (02-2004). These families include 57 index-patients with biallelic homozygous or compound heterozygous MUTYH mutations and 22 siblings with biallelic MUTYH mutations. Forty index-patients have been described previously in lesser detail.[3] One patient was reported to have CRC stage A according to the modified Astler-Coller guidelines at age 21, but after re-evaluation appeared to have high grade dysplasia (carcinoma in situ) and was not included in this series of MAP carcinomas. To date, 56% (44/79) of the carriers have developed CRC. A total of 58 CRCs were diagnosed in these 44 MAP patients, composed of 26 males and 18 females. Hematoxylin and eosin (H&E) stained slides and tissue material from 42 and 38 CRCs, respectively, belonging to 35 MAP patients, could be retrieved from 23 pathology laboratories throughout The Netherlands.
###end p 18
###begin title 19
Histological examination
###end title 19
###begin p 20
###xml 151 153 151 153 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 423 425 423 425 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 712 714 712 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 814 816 814 816 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 218 221 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
Histological tumour type and grade were independently assessed by two observers (HM and MN) according to the World Health Organization classification.[18] Staging was performed according to the modified Astler-Coller (MAC) and the American Joint Committee on Cancer (AJCC) TNM staging system guidelines. Metachronous tumours were defined as new tumours arising in the colon at least six months after the initial diagnosis.[19] Semi-quantitative assessment defined two subgroups, according to mucinous content of the tumour: >50% of tumour area involved (mucinous) and 10 to 50% of tumour area involved. Mucinous adenocarcinomas and signet-ring cell carcinoma by convention were considered poorly differentiated [18], although are also separately scored. A Crohn's-like reaction was assessed as grade 0, 1+, or 2+.[20] Grade 2+ was referred to as conspicuous. Leukocyte infiltration was assessed semi-quantitatively on H&E-slides as none, moderate (visible only on high magnification (x40), or marked (visible already on low magnification x10).
###end p 20
###begin title 21
Molecular analysis
###end title 21
###begin p 22
###xml 153 155 153 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 619 621 619 621 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 656 672 656 672 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC, KRAS2, p53 </italic>
###xml 676 682 676 682 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4 </italic>
###xml 742 746 742 746 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS</italic>
###xml 761 785 761 785 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Mutation Cluster Region </italic>
###xml 811 815 811 815 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 860 862 860 862 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 944 948 944 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 962 968 962 968 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4 </italic>
###xml 1084 1090 1084 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUTYH </italic>
###xml 1212 1213 1212 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 1214 1215 1214 1215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 1347 1349 1347 1349 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 1364 1370 1364 1370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUTYH </italic>
###xml 1443 1445 1443 1445 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 1446 1448 1446 1448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
Genomic DNA of paired normal colon and colorectal carcinoma tissue was isolated from formalin-fixed paraffin-embedded material, as described previously.[21] The percentage of tumour cells in the areas from which the punches were taken, were in all cases above 50% and in most cases above 70%. Microsatellite instability analysis was done according to the Bethesda guidelines using the markers D2S123, D5S346, D17S250, BAT25, BAT26, and BAT40. A tumour was scored MS-stable when no marker showed instability, MSI-high when > 30% of markers showed instability, and MSI-low when only one marker (<30%) showed instability.[22] For somatic mutation analysis of APC, KRAS2, p53 and SMAD4 DNA sequence analysis was performed. Codon 12 and 13 of the KRAS2 gene and the Mutation Cluster Region (codons 1286-1513) of the APC gene were analyzed as described previously. [23] Primer pairs were designed for the coding regions and exon-intron boundaries of p53 exons 5-8 and SMAD4 exons 3-13. Primer details are available from the authors upon request. Germline DNA mutation analysis of the whole MUTYH gene was performed on lymphocytic DNA or DNA from formalin-fixed paraffin-embedded normal tissue as described previously.[3,5] Primer details are available from the authors upon request. For further details see the website of our DNA diagnostic laboratory [24]. To describe MUTYH mutations we used the most up-to-date annotation, see the LOVD database.[25,26]
###end p 22
###begin title 23
Immunohistochemical analysis using tissue microarray
###end title 23
###begin p 24
###xml 119 121 119 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 274 275 274 275 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2</sub>
###xml 276 278 276 278 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 740 748 740 748 <italic xmlns:xlink="http://www.w3.org/1999/xlink">CTNNB1) </italic>
###xml 524 529 <span type="species:ncbi:10090">mouse</span>
###xml 535 540 <span type="species:ncbi:9606">human</span>
To construct a tissue microarray (TMA), triplicate tissue cores were taken from tumour tissue as described previously [27]on the basis of H&E-stained slides reviewed by a pathologist (HM).) Sections were deparaffinised and endogenous peroxidases were inactivated with 0.3% H2O2 in methanol solution after antigen retrieval by means of microwave oven treatment for 10 minutes in 10 mM citrate buffer pH 6.0 (p53, MLH1) or 1 mM Tris-EDTA pH 8.0 (beta-catenin, PMS2). Sections were incubated overnight at room temperature with mouse anti-human monoclonal antibodies directed against p53 (clone D0-7, 1:1000, Neomarkers, USA), MLH1 (clone G168-728, 1:50, BD Pharmigen, USA), PMS2 (clone A16-4, 1:200, BD Pharmigen) and beta-catenin (encoded by CTNNB1) (clone 14, 1: 800, BD Transduction Laboratories, USA). The following day, tissue sections were incubated with a biotinylated secondary antibody in PBS/BSA 1%. Diaminobenzidine tetrahydrochloride was used as a chromogen for the development of the staining. The slides were counterstained with hematoxylin. Immunohistochemistry (IHC) was scored for p53 nuclear staining as: 1 = none, 2 = >0<25% (mostly indicative of a functional intact p53 status), 3 = 25%-75%, or 4 = >75% (the latter two indicative of p53 dysfunction). Staining of beta-catenin was graded by the following scale: 1 = membranous staining, 2A = membranous and some nuclear staining, 2B = membranous staining, and increased nuclear staining, 3 = strong nuclear staining, with less or no membranous staining. Normal epithelium and stromal cells provided positive internal controls.
###end p 24
###begin title 25
Infiltrate analysis using fluorescent immunohistochemical staining
###end title 25
###begin p 26
###xml 66 68 66 68 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 812 814 811 813 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 157 163 <span type="species:ncbi:9986">rabbit</span>
###xml 205 210 <span type="species:ncbi:10090">mouse</span>
###xml 297 302 <span type="species:ncbi:10090">mouse</span>
Fluorescent immunostaining was performed as previously described.[28] Five mum TMA sections were used in all experiments. A mixture of the antibodies ab828 (rabbit polyclonal, anti-CD3; Abcam, UK), hNK-1 (mouse monoclonal IgM, anti-CD57; Department of Pathology, LUMC, The Netherlands), and 4B11 (mouse monoclonal IgG2b, anti-CD8; Novo Castra, UK) was added to each slide. The next day slides were incubated with the appropriate combination of fluorescent antibody conjugates (IgG-Alexa Fluor 546, IgM-Alexa Fluor 488 and IgG2b-Alexa Fluor 647). Alexa Fluor conjugates were obtained from Molecular Probes (Leiden, the Netherlands). The images were captured with a confocal laser scanning microscope (LSM) (Zeiss LSM510, Zeiss, Germany). The number of each leukocyte sub-type was assessed per tumour area (TILs/mm2 tumour epithelium) using the LSM software (Zeiss). Cells staining for CD3, and not for CD8 or other CD markers, were considered to be T-helper lymphocytes. Standard immunostaining for the associated cytotoxic molecule granzyme B (NCL-GRAN-B; clone 11F1; Novo Castra) was performed in sequential sections. To calculate the density of granzyme B positive cells we used the assessed tumour area from the fluorescent immunostaining.
###end p 26
###begin title 27
Literature on histological and molecular features of CRC
###end title 27
###begin p 28
We compared literature available, describing histological and molecular features, on sporadic, MSI-high and Lynch CRCs. The following terms were employed as search terms: colon carcinomas, bowel cancer, CRC, sporadic, MSI-high, Lynch, HNPCC, histological, molecular, APC, KRAS2, p53, beta-catenin, CTNNB1, SMAD4, tumour infiltrating lymphocytes, tumour infiltrating lymphocytes and intra-epithelial lymphocytes. All relevant references within articles were identified and included.
###end p 28
###begin title 29
Statistical Analysis
###end title 29
###begin p 30
###xml 165 166 165 166 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 210 211 210 211 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 450 458 <span type="species:ncbi:9606">patients</span>
###xml 467 474 <span type="species:ncbi:9606">patient</span>
Fisher exact test was used to estimate an association between molecular and clinical-pathological parameters. The Spearman test was used to assess correlations. All P-values are reported for a two-tailed test; P-values of less than 0.05 were considered to be statistically significant. A group with high and low intraepithelial leukocyte infiltration was distinguished, using the median value as cut-point of the leukocyte-infiltration scores of all patients. When a patient had more than one carcinoma the mean number of lymphocytes in these carcinomas was used for the survival analysis. The Kaplan-Meier method was used to calculate the overall survival and the log-rank test was used for comparison of the survival curves. All statistical analyses were carried out using the SPSS software package (SPSS Inc. 12.0, USA).
###end p 30
###begin title 31
Results
###end title 31
###begin title 32
Histopathology of MAP carcinomas
###end title 32
###begin p 33
###xml 63 64 63 64 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 99 100 99 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 105 106 105 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 683 684 683 684 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1A</xref>
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1B</xref>
###xml 1004 1006 1004 1006 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1C</xref>
###xml 1225 1227 1225 1227 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1D</xref>
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 113 121 <span type="species:ncbi:9606">patients</span>
###xml 530 533 <span type="species:ncbi:37162?0.34174508126603936">MAC</span>
###xml 634 642 <span type="species:ncbi:9606">patients</span>
Forty-four MAP patients were diagnosed with 58 CRCs (see Table 1) at a mean age of 49 years (Table 2 and 3). Ten patients (23%) had metachronous or synchronous carcinomas. The majority of carcinomas (35/51, 69%, metachronous tumours not included), were right-sided, i.e. proximal to the flexura lienalis. The majority of proximal tumours were located in ascending colon or cecum (80%, 28/35) and only a minority occurred in the transverse colon or hepatic flexure (14%, 5/35). Fifty-five percent (29/53) were stage B according to MAC guidelines or T>1N0M0 according to the TNM guidelines. Forty-two colon carcinomas from 35 MAP index patients were available for further study (Table 1). Histological analysis showed poor differentiation in 26% (11/42) and moderate in 71% (30/42, Figure 1A), mucinous CRCs represented 81% of these cases (9/11, Figure 1B). No MAP carcinomas showed a solid or medullary histotype or contained signet ring cells. A Crohn's like infiltrate was present in 33% (13/40, Figure 1C). In 40% (16/40) of tumours, focal necrosis (dirty necrosis within glandular lumina) was present. Tumour infiltrating lymphocytes assessed on H&E-slides were present in 74% (31/42) and were marked in 17% (7/42, Figure 1D). In 33 tumours MSI status was analyzed and all carcinomas but one were MS-stable. The latter carcinoma showed instability of less than 30% of markers (one dinucleotide marker) designating the tumour as MSI-low. Furthermore, staining for MLH1 and PMS2 was positive for all the tumours.
###end p 33
###begin p 34
###xml 0 17 0 17 <bold xmlns:xlink="http://www.w3.org/1999/xlink">MAP CRC histology</bold>
###xml 283 284 283 284 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 303 304 303 304 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 307 308 307 308 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 326 328 326 328 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 331 333 331 333 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 337 338 337 338 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
MAP CRC histology. A) moderate differentiation, tumour 23, 5x B) >50% mucinous, tumour 29, 5x C) Crohn's like infiltrate, tumour 34, 5x D) TILs, tumour 33, 40x E) p53 staining, >75% nuclear staining, tumour 32, 5x F) CD3/CD8/CD57 immunofluorescent staining, tumour 35, red cells: CD3+, purple cells: CD3+CD8+, white cells: CD3+ CD8+ CD57+, 40x.
###end p 34
###begin p 35
###xml 4 12 <span type="species:ncbi:9606">patients</span>
MAP patients and histological features of colorectal carcinomas
###end p 35
###begin p 36
Blank cells: not done/not ascertainable, CRC = colorectal cancer, R = rectum, S = sigmoid colon, DC = descending colon, SF = splenic flexure, TC = transverse colon, HF = hepatic flexure, AC = ascending colon, C = cecum, I = ileum.
###end p 36
###begin p 37
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 35 41 35 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUTYH </italic>
###xml 182 183 182 183 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 219 225 219 220 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;</bold>
###xml 255 267 250 252 <bold xmlns:xlink="http://www.w3.org/1999/xlink">&#8224;&#8224;</bold>
###xml 55 60 <span type="species:ncbi:9606">Human</span>
aAccording to the recently changed MUTYH Nomenclature (Human Genome Variation Society), adding 14 amino acids after amino acid position 53. For example: Y165C>Y179C and G382D>G396D, banalysis in DNA from FFPE material. daggerMAC = Modified Astler-Coller, daggerdaggermod = moderate, muc = mucinous, *0 = none, 1 = mild reaction, 2 = intense reaction (conspicuous),** tumour infiltrating lymfocytes 0 = none/few, + = moderate, ++ = marked, ~yes = focal necrosis (dirty necrosis within glandular lumina).
###end p 37
###begin p 38
Histological and molecular features of carcinomas
###end p 38
###begin p 39
###xml 343 347 343 347 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 400 401 400 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
CS = current study, MAP = MUTYH-associated polyposis, MSS= microsatellite stable, MSI = microsatellite instability, TIL = Tumour Infiltrating Lymphocytes, MCR = mutation cluster region. *Relative large proportion of missense mutations (29%) in study by Luchtenborg et al as compared to other studies, explaining the high overall percentage of APC mutations in the MCR only group. See Additional file 1 online for more details and article references.
###end p 39
###begin p 40
Concise overview of data in Table 2
###end p 40
###begin p 41
0 = 0-10%, + = 11-40%, ++ = 41-70%, +++ = >70% ND = no data
###end p 41
###begin p 42
* mucinous rate in MAP CRCs in this study was two times more than in sporadic CRCs: 23% and 12% respectively (see also table 2).
###end p 42
###begin p 43
No significant geno-phenotype correlations for any of the main histopathological parameters could be found.
###end p 43
###begin title 44
Somatic mutation analysis and immunohistochemical staining
###end title 44
###begin p 45
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 29 30 29 30 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUTYH </italic>
###xml 256 262 256 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 628 630 628 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1E</xref>
###xml 693 697 693 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 769 770 769 770 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 850 851 850 851 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 1010 1011 1010 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 1014 1016 1014 1016 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 1351 1354 1351 1354 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 1410 1414 1410 1414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 1526 1528 1526 1528 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1536 1537 1536 1537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 1540 1546 1540 1546 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4 </italic>
###xml 1614 1615 1614 1615 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 244 251 <span type="species:ncbi:9606">patient</span>
###xml 752 759 <span type="species:ncbi:9606">patient</span>
###xml 833 840 <span type="species:ncbi:9606">patient</span>
###xml 1115 1123 <span type="species:ncbi:9606">patients</span>
###xml 1274 1281 <span type="species:ncbi:9606">patient</span>
###xml 1312 1319 <span type="species:ncbi:9606">patient</span>
APC mutation analysis (Table 4) of the mutation cluster region showed somatic mutations in 5/36 (14%) carcinomas; four were MUTYH associated transversions (G>T's); two were C>T transitions, one of them occurring together with a G>A transition (patient 6). KRAS2 mutations were found in 23/36 (64%) of tumours, 22 were c.34G>T transversions. An increased nuclear and reduced membranous beta-catenin staining was found in 11% (4/35). In 57% (20/35) of MAP CRCs, p53 staining indicative of a functional p53 status (>0<25% nuclear staining) was found. Nuclear staining indicative of p53 dysfunction was found in 34% (12/35) (Figure 1E). In 9 out of 16 carcinomas (56%) that could be analyzed, ten p53 mutations were found. One carcinoma had two mutations (patient 7, Table 4). Three mutations were G>T transversions. Except in one case (patient 7, Table 4), staining was in concordance with the combined results of the p53 staining and LOH of chromosome 17p results published previously by Middeldorp et al (Table 4).[13] When staining was indicative of a dysfunctional p53 status, a mutation as well as LOH was found (patients 2, 23, 24, and 41). In cases were a mutation is present but no LOH was identified for 17p, staining was indicative of a still intact, functional p53 (patient 5, 8, and 16). Only one case (patient 22) had a nonsense mutation in p53, explaining the absence of nuclear staining. All other p53 mutations are (probable pathogenic) amino acid substitutions and all except one have been published previously [29](Table 4). SMAD4 mutations were present in 26% of MAP carcinomas tested (5/19, Table 4). Two tumours had G>T tranversions.
###end p 45
###begin p 46
Results of somatic mutation analysis and IHC analysis
###end p 46
###begin p 47
###xml 130 135 125 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4</italic>
###xml 143 146 138 141 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P53</italic>
###xml 149 150 144 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">@</sup>
###xml 235 237 230 232 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
Blank cells: not done/not ascertainable, dagger 0 = none, + = >0<25%, ++ = 25-75%, +++>75%, *previously reported mutations, see  (SMAD4) and  (P53), @LOH, as reported by Middeldorp et al (mainly copy neutral LOH and not physical loss),8 daggerdagger 0= category 1(membranous staining), 0/+ = 2A (membranous and some nuclear staining), + = 2B (membranous & increased nuclear staining), ++ = 3 (strong nuclear & less or no membranous staining), ~2/9 markers unstable.
###end p 47
###begin title 48
Infiltrate analysis
###end title 48
###begin p 49
###xml 218 219 218 219 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 224 225 224 225 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 235 237 235 237 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 250 252 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1F</xref>
###xml 306 307 306 307 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 312 313 312 313 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 348 349 348 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 355 356 355 356 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-</sup>
###xml 391 392 391 392 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 397 398 397 398 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 467 469 467 469 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 677 679 677 679 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 883 885 883 885 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 893 894 893 894 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 913 915 913 915 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 991 993 991 993 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1017 1019 1017 1019 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1177 1179 1177 1179 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1198 1200 1198 1200 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1266 1268 1266 1268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2A</xref>
###xml 1273 1275 1273 1275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2B</xref>
###xml 1277 1279 1277 1279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1290 1292 1290 1292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 1086 1094 <span type="species:ncbi:9606">patients</span>
###xml 1144 1152 <span type="species:ncbi:9606">patients</span>
First, we scored the presence of TILs and Crohn's like infiltrate on standard H&E sections. Secondly, in order to establish an objective lymphocytic cell count, we also performed triple-fluorescent IHC staining for CD3+, CD8+, and CD57+ TILs (Figure 1F). The median number of intra-epithelial T-helper (CD3+, CD8-), cytotoxic T lymphocyte (CTL, CD8+, CD57-) and natural killer cells (NK, CD8+/CD57+) found in 34 CRCs available for analyses were 20, 37, and 0 cells/mm2 tumour, respectively. There was a significant correlation between the total number of immunofluorescently detected TILs and the amount of TILs (none, present, marked) assessed on H&E slides (Spearman's test, P = 0.002). Immunohistochemistry for granzyme B, which is expressed on activated CD8+ cytotoxic lymphocytes (CTLs) and involved in the induction of apoptosis of target cells, showed a median of 4 granzyme B+ cells/mm2. The number of CD8+ TILs showed a significant positive correlation with the number of granzyme B+ cells (Spearman's test, P = 0.009). No significant differences in survival were seen between patients with high versus low levels of TILs, although in patients with a high level of CD8+ TILs and granzyme B+ cells, a tendency was observed towards a better prognosis (Figure 2A and 2B, P = 0.15 and P = 0.2, respectively, log rank test).
###end p 49
###begin p 50
###xml 45 47 45 47 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 68 70 68 70 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 0 76 0 76 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Survival in 26 MAP patients, according to CD8<sup>+ </sup>status and granzyme B<sup>+ </sup>status</bold>
###xml 146 148 146 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 159 160 159 160 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 176 178 176 178 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 195 196 195 196 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+</sup>
###xml 19 27 <span type="species:ncbi:9606">patients</span>
Survival in 26 MAP patients, according to CD8+ status and granzyme B+ status. high versus low, median, number of TILs as cut off point. Log rank; P = 0.15 (CD8+) and Log rank; P = 0.2 (granzyme B+).
###end p 50
###begin title 51
Literature Review
###end title 51
###begin p 52
###xml 27 28 27 28 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 33 34 33 34 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 86 87 86 87 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 98 99 98 99 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 265 266 265 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 321 322 321 322 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
Results are shown in Table 2 and 3; different study outcomes were aggregated in Table 2 and Table 3 shows concise conclusions of these data. Data on Lynch syndrome carcinomas only included proven mismatch repair gene mutation carriers. An extended version of Table 2 is available online, as a supplement (Additional file 1), showing outcomes of all the individual articles and including data for Lynch syndrome suspected carcinomas where no germline mutations in the mismatch repair genes were searched for or found.
###end p 52
###begin title 53
Discussion
###end title 53
###begin p 54
###xml 199 201 199 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 202 204 202 204 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 205 207 205 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 412 413 412 413 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 418 419 418 419 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 667 668 667 668 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 673 674 673 674 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 837 838 837 838 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 839 841 839 841 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 842 844 842 844 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 989 990 989 990 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 995 996 995 996 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1194 1196 1194 1196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 508 516 <span type="species:ncbi:9606">patients</span>
###xml 549 557 <span type="species:ncbi:9606">patients</span>
Specific histological and molecular characterization of CRCs may have implications in the diagnosis, prognosis, and treatment strategies, as demonstrated for mismatch repair deficient MSI-high CRCs.[15,16,30] In order to explore similar implications for MAP, we analyzed clinical, histological and molecular pathologic characteristics in our series of MAP CRCs and compared our findings to the literature (Table 2 and 3). Age at diagnosis of CRC, when compared to sporadic cases, was relatively young in MAP patients and comparable to that in Lynch patients (49 and 47 years). MAP CRCs showed less metastases than sporadic CRCs, but more than Lynch carcinomas (Table 2 and 3). A prominent feature is the 69% proximal sub-localization of colon carcinomas in this cohort; others reported a proximal location in 29, 43 and 46% of MAP CRCs.[4,11,31] This is still more than that reported in sporadic carcinomas (23%) but less than MSI-high or Lynch carcinomas (75% and 67% respectively, Table 2 and 3). Furthermore, this study showed that proximal MAP tumours had a preferential location in the cecum or ascending colon, as opposed to the transverse colon, which was also reported by O'Shea at al.[31]
###end p 54
###begin p 55
###xml 146 147 146 147 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 309 310 309 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 450 452 450 452 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 76 84 <span type="species:ncbi:9606">patients</span>
###xml 130 138 <span type="species:ncbi:9606">patients</span>
The relatively high number of observed (meta) synchronous carcinomas in MAP patients is in agreement with previous reports on MAP patients (Table 2). In contrast to sporadic carcinomas but in agreement with MSI-high carcinomas, MAP CRC's were demonstrated to be relatively often mucinous in this study (Table 2). O'Shea et al. found a poor (low) differentiation grade in all MAP carcinomas (16/16) but remarkably, none had a mucinous pattern (0/16).[31]
###end p 55
###begin p 56
###xml 480 482 480 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 483 485 483 485 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 486 488 486 488 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 583 589 583 589 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUTYH </italic>
###xml 925 927 925 927 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1138 1140 1138 1140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 1247 1249 1247 1249 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 1405 1406 1405 1406 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 1411 1412 1411 1412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 1612 1614 1612 1614 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 1667 1669 1667 1669 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1683 1685 1683 1685 <sup xmlns:xlink="http://www.w3.org/1999/xlink">+ </sup>
###xml 1633 1641 <span type="species:ncbi:9606">patients</span>
In MSI-high tumours the caretaker function of mismatch repair enzymes is disrupted resulting in somatic mutations that are accumulated throughout the cell genome. Such abundance of mutations can result in aberrant frameshift peptides that would be presented at the cell surface, through the antigen processing pathway, to cells of the immune system. This sequence of events could explain the presence of an accentuated intra-epithelial lymphocytic infiltrate in MSI-high tumours.[14,32,33] In MAP carcinomas the disruption of the caretaker function of the BER machinery, mediated by MUTYH mutations, leads to the accumulation of G>T somatic mutations, at least early in tumourigenesis, which might evoke similar specific anti-tumour immune responses. TILs were present in a majority of MAP CRCs (74%) in this study, although marked infiltration was only detected in about one fifth of MAP carcinomas. The median number of CD8+ lymphocytes in MAP CRCs, scored with IHC, fell somewhere between that found in MSI-stable and MSI-high CRC's (indicated by absent MLH-1 expression) previously analyzed with the same procedure in our laboratory.[34] O'Shea et al. reported the same percentage of TILs present in MAP CRCs as in their controls (50%, 8/16).[31] Their controls, however, might not be representative of sporadic CRCs, as the number of TILs reported by others in sporadic CRCs is much less (24%, Table 2 and 3). In MSI-high tumours, an active immune response by the host (represented by a high number of TILs) was also associated with a better survival, especially when associated with granzyme B positivity.[33] The group of MAP patients with a high number of CD8+ and granzyme B+ TILs showed a better overall survival, although not statistically significant for either parameters.
###end p 56
###begin p 57
###xml 14 18 14 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 154 155 154 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 160 161 160 161 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 338 342 338 342 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC </italic>
###xml 409 411 409 411 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 525 527 525 527 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 528 530 528 530 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 648 650 648 650 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2A</xref>
###xml 825 827 825 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 842 845 842 845 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 945 947 945 947 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
The number of APC mutations in the mutation cluster region found in MAP carcinomas (14%) is notably lower than that reported in sporadic CRCs (63%, Table 2 and 3). One possible explanation for the relatively small number of APC mutations could be that in MAP CRCs more mutations lay outside the mutation cluster region. In sporadic CRCs, APC mutations in the MCR represent 50-77% of all APC mutations found. [35-37] In MAP tumours (CRCs and adenomas), a substantial proportion (~60%) of mutations were found outside the MCR.[10,11] Similarly, in MSI-high CRCs noticeably more APC mutations are found when larger regions of APC were analyzed (Table 2A). Another explanation might be that distal carcinomas, which are underrepresented in our cohort, have more APC mutations than proximal tumours as shown by Luchtenborg et al.[38] In addition, APC-MCR mutations were seen in 46% (13/28) of rectum carcinomas analyzed previously in our laboratory.[39]
###end p 57
###begin p 58
###xml 224 225 224 225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 230 231 230 231 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
In agreement with data derived on MSI-high carcinomas, strong beta-catenin nuclear staining was not frequent in MAP carcinomas in this study (13% and 11%, respectively). In sporadic CRCs this rate is much higher (77%, Table 2 and 3).
###end p 58
###begin p 59
###xml 30 36 30 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 125 127 125 127 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 128 130 128 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
We found a high percentage of KRAS2 mutations in our MAP CRCs (64%), comparable to reports by Lipton et al. and Jones et al.[11,40] The vast majority (96%) were c.34G>T transversions (GGT>TGT). Intriguingly, no G>T transversions at the second nucleotide of this codon (leading to GGT> GTT) have been reported so far in MAP CRCs.
###end p 59
###begin p 60
###xml 13 19 13 19 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 173 179 173 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 228 230 228 230 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 270 276 270 276 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 307 308 307 308 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 313 314 313 314 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 436 442 436 442 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRA2S </italic>
###xml 471 473 471 473 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 505 511 505 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 563 564 563 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 572 578 572 578 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 680 686 680 686 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
In contrast, KRAS2 mutations are found on average in 29% of sporadic CRCs and 22% of sporadic MSI-high carcinomas. Furthermore, the c.34G>T tranversion comprises just 8% of KRAS2 mutations in sporadic and none in MSI-high CRCs.[12] In Lynch carcinomas the percentage of KRAS2 mutations is around 34%, Table 2 and 3) and in these carcinomas other hotspot mutations are found, namely the c.35G>A and c.38G>A, compromising 81% of detected KRA2S mutations in these tumours. [41] Previously we have shown that KRAS2 hotspot analysis can be used to detect MAP tumours.[5] Since KRAS2 mutations have been found previously in aberrant crypt foci (ACF) as well,[42] the high prevalence of KRAS2 mutations might influence tumourigenesis in MAP.
###end p 60
###begin p 61
###xml 139 141 139 141 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2A</xref>
###xml 153 157 153 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 292 293 292 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 325 331 325 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUTYH </italic>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53 </italic>
###xml 545 547 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 851 853 851 853 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
Nuclear staining indicative of p53 dysfunction was found in 34% in this study, which is less than found in sporadic carcinomas (57%, Table 2A). We found p53 mutations in 60% of carcinomas analyzed; this finding, along with the presence of LOH, correlated with the IHC staining results (Table 4). Three mutations were typical MUTYH G>T transversions. Lipton et al. found nuclear staining in 53% of MAP carcinomas, but p53 mutations in only 21% (of which a minority were G>T transversions), suggesting an alternative mechanism of over-expression.[11] The employment of tissue arrays for the current study could imply an underestimation of cases with both p53 and beta-catenin accumulation in the nucleus. However, we reported that 3 punches representing one tumour in a TMA correctly recapitulated the observations made on analysis of the whole slides.[27].
###end p 61
###begin p 62
###xml 0 6 0 6 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4 </italic>
###xml 72 73 72 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 107 113 107 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4 </italic>
###xml 200 202 200 202 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
SMAD4 somatic mutations in this series were present in 26% (5/19, Table 4). Lipton et al. did not find any SMAD4 mutations in MAP CRCs, but did find 18q LOH at the same frequency as in sporadic CRCs.[11] Recently we reported that the chromosome 18q LOH in MAP carcinomas mainly comprises copy neutral LOH and not physical loss, as observed in sporadic CRC.[13]
###end p 62
###begin p 63
###xml 137 143 137 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 147 150 147 150 <italic xmlns:xlink="http://www.w3.org/1999/xlink">APC</italic>
###xml 227 233 227 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SMAD4 </italic>
###xml 237 240 237 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p53</italic>
###xml 454 456 454 456 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 457 459 457 459 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 549 553 549 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MLH1</italic>
In the early stages of MAP tumourigenesis, a dominance of the BER defect can be concluded from the high frequency of G>T tranversions in KRAS2 and APC. In the later stages such G>T transversions seem less prominent, as seen in SMAD4 and p53. Mitotic recombination might be a driving force in MAP carcinogenesis, based on our conclusion that the LOH in MAP carcinomas mainly comprise copy neutral LOH. Two previous studies by Colebatch and Lefevre et al.[43,44] have suggested that MAP CRCs can also develop through a MSI pathway (by inactivation of MLH1) because of the finding of MSI-high phenotype in one out of three and one out of six MAP CRCs, respectively. O'Shea et al. found MMR deficiency in 2 out of 11 tumours (18%). However, on the basis of the results of this study (an absence of MSI-high in 35 analyzed carcinomas), we conclude that the MSI pathway is not an important pathway in the development of MUTYH associated tumours.
###end p 63
###begin title 64
Conclusion
###end title 64
###begin p 65
###xml 592 598 592 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 644 650 644 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KRAS2 </italic>
###xml 758 764 758 764 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MUTYH </italic>
###xml 727 735 <span type="species:ncbi:9606">patients</span>
MAP CRCs as a group show specific histological features that differentiate them from sporadic CRCs, and have similarities with sporadic MSI-high and Lynch syndrome colon cancers, such as a preferential proximal location, mucinous histotype, and increased presence of TILs. These TILs might suggest that defects in base excision repair, similar to mismatch repair deficiency, produce secondary aberrant proteins functioning as tumour-specific neoantigens that, in turn, induce anti-tumour immune responses. Further evidence for MAP can be assembled by the detection of c.34G>T transversion in KRAS2 that takes place in early tumour development. KRAS2 analysis can be implemented as a pre-screening test that helps selecting CRC patients eligibly for germline MUTYH mutation testing. In practice, above features should direct the pathologist towards a MAP aetiology of CRC as an alternative for a mismatch repair deficient cause, especially when diagnosed at a young age and in combination with polyps and/or a recessive inheritance pattern.
###end p 65
###begin title 66
Competing interests
###end title 66
###begin p 67
The authors declare that they have no competing interests.
###end p 67
###begin title 68
Authors' contributions
###end title 68
###begin p 69
MN, NFCCM, MvP, AM, RvE and CMJT carried out the molecular genetic studies. MN, NFCCM, MvP, AM and RvE carried out the sequence analyses. MN, MvP, RvE, CMJT, AM, HFAV, FJH and HM carried out the acquisition, analysis and interpretation of data. MN and NFCCM performed the statistical analysis. MN, NFCCM, HFAV, FJH and HM drafted the manuscript. ESJ carried out the immunoassays. MN, NFCCM, ESJ, TvW, FJH and HM participated in the design of the study. NFCCM, ESJ, TvW, HFAV, FJH and HM revised the manuscript critically for important intellectual content. HM participated in its design and coordination. All authors read and approved the final manuscript.
###end p 69
###begin title 70
Pre-publication history
###end title 70
###begin p 71
The pre-publication history for this paper can be accessed here:
###end p 71
###begin p 72

###end p 72
###begin title 73
Supplementary Material
###end title 73
###begin title 74
Additional file 1
###end title 74
###begin p 75
###xml 0 71 0 71 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Histological and molecular features in carcinomas, extended version of </bold>
###xml 77 78 77 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 228 229 223 224 <sup xmlns:xlink="http://www.w3.org/1999/xlink">@</sup>
###xml 314 316 309 311 <sup xmlns:xlink="http://www.w3.org/1999/xlink">8 </sup>
Histological and molecular features in carcinomas, extended version of table 2. Blank cells: not done/not ascertainable, dagger0 = none, + = >0<25%, ++ = 25-75%, +++>75%, *previously reported mutations, see  (SAMD4) and  (P53), @LOH, as reported by Middeldorp et al (mainly copy neutral LOH and not physical loss),8 daggerdagger0 = category 1(membranous staining), 0/+ = 2A (membranous and some nuclear staining), + = 2B (membranous & increased nuclear staining), ++ = 3 (strong nuclear & less or no membranous staining), **+ = nuclear staining, heterogenous= absent nuclear staining in part of tumour tissue, 0= no nuclear staining +/-/+/- = weak nuclear staining, ~ 2/9 markers unstable.
###end p 75
###begin p 76
Click here for file
###end p 76
###begin title 77
Acknowledgements
###end title 77
###begin p 78
We would like to thank the following hospitals (pathology departments) for providing tissue blocks: Academical Medical Center (Amsterdam), Amphia hospital (Breda), Atrium Medical Center (Heerlen), Bethesda hospital (Hoogeveen), Bronovo hospital (Den Haag), Isala hospital (Zwolle), Jeroen Bosch hospital (Den Bosch), Erasmus Medical Center (Rotterdam), Laboratorium Pathologie Oost Nederland (LabPON, Enschede), Laboratoria voor Pathologie en Medische Microbiologie (PAMM, Eindhoven/Veldhoven), Meander hospital (Amersfoort), Medisch Centrum Haaglanden (Den Haag), the Netherlands Cancer Insitute (Amsterdam), Onze Lieve Vrouwe Gasthuis (Amsterdam), Radboud University Nijmegen Medical Center (Nijmegen), Reinier de Graaf Groep (SSDZ, Delft), Rijnland Hospital (Leiderdorp), University Medical Center Utrecht (Utrecht), University Medical Center Groningen (Groningen), VieCuri, Medical Centre (Venlo and Venray), VU University Medical Center (Amsterdam), Zaans Medisch Centrum (Zaanstad).
###end p 78
###begin article-title 79
Association between biallelic and monoallelic germline MYH gene mutations and colorectal cancer risk
###end article-title 79
###begin article-title 80
###xml 17 25 <span type="species:ncbi:9606">patients</span>
MYH mutations in patients with attenuated and classic polyposis and with young-onset colorectal cancer without polyps
###end article-title 80
###begin article-title 81
###xml 72 80 <span type="species:ncbi:9606">patients</span>
Multiplicity in polyp count and extracolonic manifestations in 40 Dutch patients with MYH associated polyposis coli (MAP)
###end article-title 81
###begin article-title 82
###xml 37 45 <span type="species:ncbi:9606">patients</span>
MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype
###end article-title 82
###begin article-title 83
###xml 18 26 <span type="species:ncbi:9606">Patients</span>
Identification of Patients with (Atypical) MUTYH-Associated Polyposis by KRAS2 c.34G > T Prescreening Followed by MUTYH Hotspot Analysis in Formalin-Fixed Paraffin-Embedded Tissue
###end article-title 83
###begin article-title 84
Identification of MYH mutation carriers in colorectal cancer: a multicenter, case-control, population-based study
###end article-title 84
###begin article-title 85
Germline susceptibility to colorectal cancer due to base-excision repair gene defects
###end article-title 85
###begin article-title 86
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Contribution of common monoallelic MUTYH gene variants in German patients with familial colorectal cancer
###end article-title 86
###begin article-title 87
The role of MYH gene in genetic predisposition to colorectal cancer: another piece of the puzzle
###end article-title 87
###begin article-title 88
Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumours
###end article-title 88
###begin article-title 89
Carcinogenesis in MYH-associated polyposis follows a distinct genetic pathway
###end article-title 89
###begin article-title 90
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study
###end article-title 90
###begin article-title 91
High frequency of copy-neutral LOH in MUTYH-associated polyposis carcinomas
###end article-title 91
###begin article-title 92
High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability
###end article-title 92
###begin article-title 93
Histopathological identification of colon cancer with microsatellite instability
###end article-title 93
###begin article-title 94
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
###end article-title 94
###begin article-title 95
###xml 51 56 <span type="species:ncbi:9606">human</span>
Type, density, and location of immune cells within human colorectal tumours predict clinical outcome
###end article-title 95
###begin article-title 96
Multiple carcinomas of the large intestine: a review of the literature and a study of 261 cases
###end article-title 96
###begin article-title 97
Crohn's-like lymphoid reaction and colorectal carcinoma: a potential histologic prognosticator
###end article-title 97
###begin article-title 98
Microsatellite instability, immunohistochemistry, and additional PMS2 staining in suspected hereditary nonpolyposis colorectal cancer
###end article-title 98
###begin article-title 99
A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer
###end article-title 99
###begin article-title 100
Duodenal carcinoma in MUTYH-associated polyposis coli
###end article-title 100
###begin article-title 101
LUMC, DNA-diagnostics
###end article-title 101
###begin article-title 102
Leiden Open Variation Database
###end article-title 102
###begin article-title 103
LOVD: easy creation of a locus-specific sequence variation database using an "LSDB-in-a-box" approach
###end article-title 103
###begin article-title 104
Conventional and tissue microarray immunohistochemical expression analysis of mismatch repair in hereditary colorectal tumours
###end article-title 104
###begin article-title 105
Four-color staining combining fluorescence and brightfield microscopy for simultaneous immune cell phenotyping and localization in tumor tissue sections
###end article-title 105
###begin article-title 106
The p53 WebB Site
###end article-title 106
###begin article-title 107
###xml 25 33 <span type="species:ncbi:9606">patients</span>
Better survival rates in patients with MLH1-associated hereditary colorectal cancer
###end article-title 107
###begin article-title 108
Pathological features of colorectal carcinomas in MYH-associated polyposis
###end article-title 108
###begin article-title 109
Hereditary nonpolyposis colorectal cancer: an approach to the selection of candidates to genetic testing based on clinical and molecular characteristics
###end article-title 109
###begin article-title 110
###xml 101 109 <span type="species:ncbi:9606">patients</span>
Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis
###end article-title 110
###begin article-title 111
Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis
###end article-title 111
###begin article-title 112
APC mutations and other genetic and epigenetic changes in colon cancer
###end article-title 112
###begin article-title 113
Characteristics of somatic mutation of the adenomatous polyposis coli gene in colorectal tumours
###end article-title 113
###begin article-title 114
Somatic mutations of the APC gene in colorectal tumours: mutation cluster region in the APC gene
###end article-title 114
###begin article-title 115
APC mutations in sporadic colorectal carcinomas from The Netherlands Cohort Study
###end article-title 115
###begin article-title 116
Progression and tumor heterogeneity analysis in early rectal cancer
###end article-title 116
###begin article-title 117
Increased frequency of the k-ras G12C mutation in MYH polyposis colorectal adenomas
###end article-title 117
###begin article-title 118
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status
###end article-title 118
###begin article-title 119
Mutant KRAS in aberrant crypt foci (ACF): initiation of colorectal cancer?
###end article-title 119
###begin article-title 120
The role of MYH and microsatellite instability in the development of sporadic colorectal cancer
###end article-title 120
###begin article-title 121
Implication of MYH in colorectal polyposis
###end article-title 121

